10 U/ml (OR 2.86, p 0.01) remained the only independent factors to predict ovarian cancer recurrence. Conclusions The present paper proposes the validation of a novel CA125 algorithm aiming to detect recurrent EOC. These data may allow us to investigate novel ways of follow up that do not require a patient's physical attendance at a clinic (virtual follow-up)."/>
Variables | HR | 95% CI | Â | P |
---|---|---|---|---|
CA125 doubling | 5.10 | 1.11 | 23.43 | 0.036 |
FIGO stages 3 or 4 vs stage 1 or 2 | 1.52 | 0.28 | 8.30 | 0.629 |
Nadir CA125 levels > 10 U/ml | 2.86 | 1.29 | 6.37 | 0.010 |
Residual disease (any vs. nil) | 1.06 | 0.48 | 2.33 | 0.893 |
Cell type (serous vs. other) | 1.52 | 0.55 | 4.15 | 0.417 |